Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by AlloVir
AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer
May 16, 2023
From
AlloVir
Via
Business Wire
Tickers
ALVR
AlloVir Reports First Quarter 2023 Financial Results
May 04, 2023
From
AlloVir
Via
Business Wire
Tickers
ALVR
AlloVir Appoints Derek Adams, Ph.D., to Board of Directors
February 23, 2023
From
AlloVir
Via
Business Wire
Tickers
ALVR
AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition
December 10, 2022
From
AlloVir
Via
Business Wire
Tickers
ALVR
AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 15, 2022
From
AlloVir
Via
Business Wire
Tickers
ALVR
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant Patients
April 20, 2022
From
AlloVir
Via
Business Wire
Tickers
ALVR
AlloVir Appoints Shawn Tomasello to Its Board of Directors
March 31, 2022
From
AlloVir
Via
Business Wire
Tickers
ALVR
AlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant Patients
March 22, 2022
From
AlloVir
Via
Business Wire
Tickers
ALVR
AlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
February 11, 2022
From
AlloVir
Via
Business Wire
Tickers
ALVR
AlloVir Reports Full-Year 2021 Financial Results and 2022 Outlook
February 10, 2022
From
AlloVir
Via
Business Wire
Tickers
ALVR
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transplantation
January 05, 2022
From
AlloVir
Via
Business Wire
Tickers
ALVR
AlloVir to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 03, 2022
From
AlloVir
Via
Business Wire
Tickers
ALVR
AlloVir Announces Departure of Chief Medical Officer Augustin Melian
December 16, 2021
From
AlloVir
Via
Business Wire
Tickers
ALVR
AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting
December 11, 2021
From
AlloVir
Via
Business Wire
Tickers
ALVR
AlloVir to Host Virtual Investor Event
December 02, 2021
From
AlloVir
Via
Business Wire
AlloVir Reports Third Quarter 2021 Financial Results
November 05, 2021
From
AlloVir
Via
Business Wire
Tickers
ALVR
AlloVir Reports Second Quarter 2021 Financial Results
August 06, 2021
From
AlloVir
Via
Business Wire
Tickers
ALVR
AlloVir Reports First Quarter 2021 Financial Results
May 06, 2021
From
AlloVir
Via
Business Wire
Tickers
ALVR
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.